The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.

The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.

Provided are methods of preparing 3-R-1,4,2-dioxazol-5-one compounds using convenient and efficient methods. Also provided are 3-R-1,4,2-dioxazol-5-one compounds produced using the methods described.

Provided are methods of preparing 3-R-1,4,2-dioxazol-5-one compounds using convenient and efficient methods. Also provided are 3-R-1,4,2-dioxazol-5-one compounds produced using the methods described.

The present invention provides a method for controlling a soybean rust fungus having an amino acid substitution of F129L on mitochondrial cytochrome b protein. According to the present invention, a compound represented by formula (I) [wherein R.sup.1 represents a C1-C3 chain hydrocarbon group and so on, n is 0, 1, 2 or 3, and when is 2 or 3, a plural of R.sup.2 may be identical to or different from each other, and R.sup.2 represents a C1-C3 chain hydrocarbon group and so on, Q represents a group represented by Q1 (where • represents a binding site to a benzene ring) and so on, L.sup.1 represents CH.sub.2 or an oxygen atom, and E represents a C1-C6 alkyl group and so on.] can use to control a soybean rust fungus having an amino acid substitution of F129L on mitochondrial cytochrome b protein.

##STR00001##

##STR00002##

##STR00003##

##STR00004##

Disclosed herein are pharmaceutical compositions comprising biosynthetic allosteric mTOR inhibitors that can have improved pharmacology and reduced toxicity. Also disclosed herein are methods of treating a condition or disease by administering biosynthetic allosteric mTOR inhibitors.

Engineered non-plant cells that produce a benzylisoquinoline alkaloid product that is a derivative of canadine along a metabolic pathway that converts canadine, or an analog of canadine, to a noscapinoid product are provided. Methods of culturing engineered non-plant cells that produce a noscapinoid product and pharmaceutical compositions are also provided.

Engineered non-plant cells that produce a benzylisoquinoline alkaloid product that is a derivative of canadine along a metabolic pathway that converts canadine, or an analog of canadine, to a noscapinoid product are provided. Methods of culturing engineered non-plant cells that produce a noscapinoid product and pharmaceutical compositions are also provided.

The present invention relates to a pharmaceutical composition for preventing or treating small cell lung cancer associated with a RON mutation and a method using the same. The compound according to the present invention may be usefully used as a precision medicine in the treatment of a patient with small cell lung cancer which has resistance to an EGFR-targeted therapeutic agent used in conventional anticancer therapy and has the RONΔ155, RONΔ160, and RONΔ165 mutations.

The present invention relates to a pharmaceutical composition for preventing or treating small cell lung cancer associated with a RON mutation and a method using the same. The compound according to the present invention may be usefully used as a precision medicine in the treatment of a patient with small cell lung cancer which has resistance to an EGFR-targeted therapeutic agent used in conventional anticancer therapy and has the RONΔ155, RONΔ160, and RONΔ165 mutations.